公开(公告)号：US20150241443A1

公开(公告)日：2015-08-27

申请号：US14697455

申请日：2015-04-27

Applicant: Electrophoretics Limited

Inventor： Peter Schulzknappe ,  Ian Pike ,  Karsten Kuhn

IPC: G01N33/68

CPC classification number: G01N33/58 ,  G01N1/28 ,  G01N33/6848 ,  G01N33/6851 ,  G01N33/96 ,  G01N2001/2893 ,  G01N2333/4703 ,  G01N2333/765 ,  G01N2333/775 ,  G01N2458/15 ,  G01N2560/00 ,  G01N2570/00 ,  H01J49/0009 ,  Y10T436/105831

Abstract: Provided is a method of assaying for an analyte, including combining a test sample having the analyte, with a calibration sample having at least two different aliquots of the analyte, each aliquot having a different known quantity of the analyte. The test sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry. The method further includes determining by mass spectrometry the quantity of analyte in the test sample and in each aliquot, and calibrating the quantity of analyte in the test sample against known and determined quantities of analytes in the aliquots.

Abstract translation: 提供了一种分析分析物的方法，包括将具有分析物的测试样品与具有至少两个不同等分试样的分析物的校准样品结合，每个等分试样具有不同的已知量的分析物。 测试样品和每个等分试样用一个或多个具有质谱分辨质量标记物组的等压质量标记进行差异标记，使得可以通过质谱法区分测试样品和校准样品的每个等分试样。 该方法还包括通过质谱法测定测试样品和各等分试样中的分析物的量，并根据等分试样中已知和确定量的分析物校准测试样品中的分析物的量。

公开(公告)号：US20150241436A1

公开(公告)日：2015-08-27

申请号：US14398700

申请日：2013-05-03

Applicant: Whitehead Institute for Biomedical Research ,  The Brigham and Women's Hospital, Inc.

Inventor： Sandro Santagata ,  Susan Lindquist ,  Marc Mendillo ,  Luke J. Whitesell

IPC: G01N33/574

CPC classification number: G01N33/57496 ,  G01N33/5011 ,  G01N33/57415 ,  G01N33/6875 ,  G01N2333/4703 ,  G01N2500/10 ,  G01N2800/52

Abstract: In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer. In some aspects, the invention relates to the HSF1 cancer program genes, HSF1 cancer signature set genes, subsets thereof, and uses in tumor diagnosis, prognosis, treatment-specific prediction, treatment selection, or drug discovery, among others.

Abstract translation: 在一些方面，本发明涉及热休克蛋白-1（HSF1）基因和HSF1基因产物。 在一些方面，本发明提供了肿瘤诊断，预后，治疗特异性预测或治疗选择的方法，所述方法包括评估从肿瘤获得的样品中HSF1表达或HSF1活化的水平。 在一些方面，本发明涉及增加的HSF1表达和增加的HSF1激活与癌症例如乳腺癌中的不良结果相关的发现。 在一些方面，本发明涉及HSF1癌症程序基因，HSF1癌症签名集合基因，其子集，以及肿瘤诊断，预后，治疗特异性预测，治疗选择或药物发现等中的用途。

公开(公告)号：US09107918B2

公开(公告)日：2015-08-18

申请号：US13203810

申请日：2010-03-12

Applicant: Masahiko Nishiyama ,  Keiko Hiyama ,  Keiji Tanimoto

Inventor： Masahiko Nishiyama ,  Keiko Hiyama ,  Keiji Tanimoto

IPC: C12Q1/68 ,  C12P19/34 ,  A61K31/4745 ,  G01N33/574 ,  C07H21/02

CPC classification number: A61K31/4745 ,  C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2333/916 ,  G01N2333/96466 ,  G01N2333/988 ,  G01N2800/52

Abstract: To provide a method for determining the sensitivity of a patient to irinotecan, SN-38, and/or a salt thereof, which method can determine the therapeutic response of the patient and to provide a novel cancer therapeutic means employing the method.The method for determining the sensitivity of a subject to irinotecan, SN-38, and/or a salt thereof includes measuring the expression levels of AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene, and TBX3 gene in a specimen, and calculating the best tumor response rate (%), overall survival (days), or progression-free survival (days) from formulas (1) to (3).

Abstract translation: 为了提供一种用于确定患者对伊立替康，SN-38和/或其盐的敏感性的方法，该方法可以确定患者的治疗反应并提供采用该方法的新型癌症治疗方法。 用于测定受试者对伊立替康，SN-38和/或其盐的敏感性的方法包括测定AMD1基因，CTSC基因，EIF1AX基因，C12orf30基因，DDX54基因，PTPN2基因和TBX3基因的表达水平 （1）至（3）的最佳肿瘤反应率（％），总生存期（天）或无进展生存期（天）计算。

公开(公告)号：US20150224104A1

公开(公告)日：2015-08-13

申请号：US14426114

申请日：2013-09-09

Applicant: Celgene Corporation

Inventor： Anita Gandhi ,  Jorge Dimartino ,  Rajesh Chopra

IPC: A61K31/5377 ,  G01N33/574 ,  A61K45/06 ,  A61K31/454 ,  A61K31/517

CPC classification number: A61K31/5377 ,  A61K31/445 ,  A61K31/454 ,  A61K31/517 ,  A61K45/06 ,  G01N33/57415 ,  G01N2333/4703 ,  A61K2300/00

Abstract: Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

Abstract translation: 本文提供了治疗，预防和/或控制局部晚期乳腺癌（包括炎性乳腺癌）的方法，其包括向患者施用一种或多种免疫调节化合物或其对映体或其对映异构体或其药学上可接受的盐，溶剂合物，水合物， 共晶，包合物或其多晶型物。

公开(公告)号：US20150219624A1

公开(公告)日：2015-08-06

申请号：US14693832

申请日：2015-04-22

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Hans-Guido WENDEL ,  Andrew Wolfe ,  Kamini Sing ,  Yi Zhong ,  Phillip Drewe

IPC: G01N33/50 ,  G01N33/574 ,  A61K31/429 ,  A61K31/357 ,  A61K31/58

CPC classification number: G01N33/5011 ,  A61K31/343 ,  A61K31/357 ,  A61K31/429 ,  A61K31/58 ,  G01N33/57496 ,  G01N33/582 ,  G01N2333/4703 ,  G01N2333/914 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/52

Abstract: Methods are provided for identifying agents capable of modulating cap-dependent RNA translation by comparing translation efficiency in the presence and absence of the agent in an in-vitro or in-vivo translation system that comprises eIF4A and an mRNA having one or more eIF4A-dependent translation-controlling motifs. The modulation of translation in the presence of the agent indicates the agent as capable of modulating cap-dependent mRNA translation. The method can be used to identify anti-cancer agents and oncogenes that may be responsible for tumorigenesis.

Abstract translation: 提供了通过比较包含eIF4A和具有一个或多个eIF4A依赖性的mRNA的体外或体内翻译系统中存在和不存在试剂的翻译效率来鉴定能够调节帽依赖性RNA翻译的方法的方法 翻译控制图案。 在试剂存在下调节翻译表明该试剂能够调节帽依赖性mRNA翻译。 该方法可用于鉴定可能导致肿瘤发生的抗癌剂和致癌基因。

公开(公告)号：US20150211075A1

公开(公告)日：2015-07-30

申请号：US14679889

申请日：2015-04-06

Applicant: AbbVie Inc.

Inventor： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4703

Abstract: The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.

Abstract translation: 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。

公开(公告)号：US20150198618A1

公开(公告)日：2015-07-16

申请号：US14672908

申请日：2015-03-30

Applicant: Integrated Diagnostics, Inc.

Inventor： Xiao-Jun Li ,  Paul Edward Kearney

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2333/4703 ,  G01N2333/775 ,  G01N2333/811 ,  G01N2333/91085 ,  G01N2333/916 ,  G01N2800/2821 ,  G01N2800/60

Abstract: Novel compositions, methods, assays and kits directed to a diagnostic panel for Alzheimer's disease are provided. In one embodiment, the diagnostic panel includes one or more proteins associated with Alzheimer's disease.

Abstract translation: 提供了针对阿尔茨海默病诊断小组的新型组合物，方法，测定和试剂盒。 在一个实施方案中，诊断面板包括与阿尔茨海默病相关的一种或多种蛋白质。

公开(公告)号：US20150198617A1

公开(公告)日：2015-07-16

申请号：US14677053

申请日：2015-04-02

Applicant: Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

Abstract translation: 提供了用于确定血脑屏障（BBB）损伤并治疗可能由于缺血事件而遭受BBB损伤的患者的方法和装置。 所述方法和装置涉及检测血液样品中裂解的闭合蛋白片段的存在。 根据一些实施方案，该方法进一步提供基于样品中闭合蛋白片段的浓度确定BBB损伤的程度。 在进一步的实施方案中，本公开提供用于检测血液样品中闭合蛋白片段的存在的试剂盒。

公开(公告)号：US20150197818A1

公开(公告)日：2015-07-16

申请号：US14664346

申请日：2015-03-20

Applicant: Oslo universitetssykehus HF

Inventor： Heidi Lyng ,  Malin Lando

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57411 ,  G01N2333/4703 ,  G01N2333/4704 ,  G01N2333/4706 ,  G01N2333/91131

Abstract: The present invention relates to biomarkers for chemoradioresistant subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer.

Abstract translation: 本发明涉及宫颈癌化学抗性亚型的生物标志物。 具体地说，本发明涉及一种用于预测受治疗者耐化学抗癌宫颈癌的倾向性的方法，用于诊断受试者中抗放化抗癌宫颈癌的方法，预测子宫颈癌患者宫颈癌复发可能性的方法 以及用于预测耐药性子宫颈癌患者预后的方法。

公开(公告)号：US09079909B2

公开(公告)日：2015-07-14

申请号：US13791205

申请日：2013-03-08

Applicant: Usher III Initiative

Inventor： Roland Werner Bürli ,  William Rameshchandra Krishna Esmieu ,  Christopher James Lock ,  Karine Fabienne Malagu ,  Andrew Pate Owens ,  William E Harte

IPC: C07D487/04 ,  A61K31/40 ,  C07C243/28 ,  C07D495/04 ,  C07C251/86 ,  C07D519/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K31/5025 ,  A61K31/165 ,  A61K31/167 ,  A61K31/40 ,  C07C243/28 ,  C07C251/86 ,  C07C2602/08 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00 ,  G01N33/502 ,  G01N33/6848 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2400/40 ,  G01N2500/04 ,  G01N2500/10

Abstract: Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

Abstract translation: 本文描述了用于治疗视网膜退行性疾病的化合物，组合物和方法，例如色素性视网膜炎，Leber先天性黑素瘤，综合性视网膜变性，年龄相关性黄斑变性和Usher综合征，以及与Usher综合征相关的听力损失。